

FLUORESCENCE IN SITU HYBRIDIZATION (FISH) ANALYSIS REPORT

Patient Name:	SAMPLE, JOHN	Cytogenetics Number:	NXX-XXXX
Date of Birth:	01/01/1981	Customer Specimen ID:	xxxxx
Sex:	Male	Collection Date:	04/03/2016
Specimen Type:	BONE MARROW	Received Date:	04/03/2016
Physician:	JANE DOCTOR, M.D.	Requested Date:	04/03/2016
Clinical Data:	RULE OUT MULTIPLE MYELOMA	Reported Date:	04/04/2016

Results: Abnormal FISH result for D13S25/LAMP1 (Biocare), TP53/D17Z1 (Biocare)

FISH ANALYSIS

Probe	Chromosome Target	Result
D13S25/LAMP1 (Biocare)	13q14.3/13q34	Positive
TP53/D17Z1 (Biocare)	17p13.1	See Comments
CKS1B/CDKN2C (Cytocell)	1q21/1p32.3	Negative
IGH/FGFR3 (Biocare)	t(4;14)(p16;q32)	Negative

FISH INTERPRETATION

- A deletion of D13S25 at 13q14.3 and LAMP1 at 13q34 was seen in 130 out of 200 (65.00%) interphase nuclei examined in CD138 enriched cells, indicating either a deletion of both D13S25 and LAMP1, or a possible monosomy 13. This result exceeds our lab cutoff for positivity of 1.5% for this signal pattern.**
- No evidence of a deletion of TP53 at 17p13.1 was seen in 200 interphase nuclei examined in CD138 enriched cells. However, 29 out of 200 (14.50%) interphase nuclei showed three signals for D17Z1 at the chromosome 17 centromere. This result exceeds our lab cutoff for positivity of 1.0% for this signal pattern.**
- There was no evidence of a deletion of CDKN2C at 1p32.3 or amplification of CKS1B at 1q21 in 200 interphase nuclei examined in CD138 enriched cells.
- No evidence of the t(4;14)(p16;q32) was seen in 200 interphase nuclei examined in CD138 enriched cells.



DELETIONS OF D13S25 AND LAMP1 AND LOSS (MONOSOMY) OF CHROMOSOME 13 ARE ASSOCIATED WITH MULTIPLE MYELOMA.

JANE DOCTOR, M.D.
SAMPLE HOSPITAL
1234 MEDICAL CENTER DRIVE
CITY, ST 00000



FLUORESCENCE IN SITU HYBRIDIZATION (FISH) ANALYSIS REPORT

Patient Name: SAMPLE, JOHN	Cytogenetics Number: NXX-XXXX
Date of Birth: 01/01/1981	Customer Specimen ID: XXXXX



CPT Codes: 88112, 88377x4

A control subject processed simultaneously showed a normal signal pattern in all 40 interphase nuclei examined.

ISCN Diagnosis (CDKN2C,CKS1B)x2[199/200], (FGFR3,IGH)x2[197/200], (D13S25,LAMP1)x1[130/200], (TP53x2,D17Z1x3)[29/200]

Note: These FISH tests were developed and their performance characteristics determined by Diagnostic Cytogenetics, Inc.. They have not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. These tests are used for clinical purposes. They should not be regarded as investigational or for research. This laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing.

Reviewed By:

KATHLEEN LEPPIG, M.D.

JANE DOCTOR, M.D.
SAMPLE HOSPITAL
1234 MEDICAL CENTER DRIVE
CITY, ST 00000

